2 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $2M | -$4M | 29.6% | -162.9% | — | — | $1M |
| 2024 | $2M | -$6M | 20.6% | -324.0% | — | — | $2M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $353375 | -$2M | 17.8% | -408.4% | — | — | $4M |
| Mar '25 | $553820 | -$764577 | 29.9% | -139.4% | — | — | — |
How the market has priced AIDX against its own fundamentals since 2026-02 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 1 years, 20/20 Biolabs, Inc.'s revenue has grown 16.7% per year. These are computed facts, not advice.
As of FY2025, 20/20 Biolabs, Inc. reported — of total debt against $1M of cash; operating income covered interest expense -21.3×.
In FY2025, gross margin was 29.6%, operating margin -162.9%, and net margin -182.8%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.